Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings develops and commercializes veterinary medical devices and biomedical therapeutics for companion animals and equines through PetVivo Animal Health and PetVivo AI. Its recurring company updates center on Spryng with OsteoCushion Technology, a veterinarian-administered intra-articular injection for joint-related conditions including lameness and osteoarthritis, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use.
News also covers regulatory acknowledgements, product availability, licensing and commercialization activity, PetVivo.ai and AgenticPet AI technology, fiscal results, conference presentations, and capital-market communications. The company describes a strategy of applying human therapies to animal health and protects its biomaterials, products, production processes and methods of use through patents and trade secrets.
PetVivo (OTCQX: PETV) reported fiscal 2026 Q4 operational and full-year financial results and scheduled a June 29, 2026 earnings call. Key highlights include Health Canada authorization of Spryng as a veterinary medical device in Canada, with commercialization expected near late July.
PetVivo advanced its PetVivo.ai SaaS veterinary platform, reporting beta clients cut customer acquisition costs by 50%–90% to under $43 and targeting 80%–90% gross margins. The company also announced an acquisition agreement for PiezoBioMembrane, adding patented piezoelectric biomaterial technologies, subject to customary closing conditions.
PetVivo Holdings (OTCQX: PETV) will report financial results for the year ended March 31, 2026, on Monday, June 29, 2026, after market close. A conference call and live webcast are scheduled for 5:00 p.m. CT (6:00 p.m. ET) the same day.
PetVivo Holdings (OTCQX: PETV) agreed to acquire PiezoBioMembrane, a developer of functional biomaterials and piezoelectric technologies, via a merger.
PBM shareholders will receive 3,000,000 PETV shares, partly subject to milestone-based retention. The deal adds PBM’s biomaterials, patents, know-how, and clinical and regulatory assets, supporting medical device and therapeutic development in animal and human health. Closing depends on due diligence, financing, and other customary conditions.
PetVivo Holdings (OTCQX: PETV) will host a virtual investor event, “What Veterinarians Are Seeing and How Access Is Expanding,” on Tuesday, June 16, 2026, at 1 p.m. ET.
The session will cover Spryng with OsteoCushion Technology, veterinary feedback, and expanded sales and distribution access.
Peer To Peer Network announced that partner Tier 1 AI signed PetVivo Holdings (OTCQX:PETV) as an enterprise client to deploy an investor-intelligence solution across PETV's digital ecosystem on April 29, 2026.
Under the agreement Tier 1 AI will install three tags, deliver up to 3,000 investor profiles per month, and run a three-month trial across PETV sites (petvivo.com, petvivo.ai, petvivoanimalhealth.com). This is Tier 1 AI's ninth deployment and PTOP's third enterprise customer.
PetVivo Holdings (OTCQX: PETV) will present at the Market Movers Investor Summit on May 5, 2026 at 9:40 AM ET at 48 Wall Street (the historic Bank of New York).
CEO John Lai will deliver a company presentation and hold one-on-one investor meetings. The company will discuss lead products Spryng (an intra-articular ECM microparticle device) and PrecisePRP (an off-the-shelf, leucoreduced, allogeneic PRP with 4 billion platelets per vial at 500,000 platelets/µL and <1500 WBC/µL).
PetVivo (OTCQX: PETV) reported fiscal Q3 and first nine months results ended Dec 31, 2025 and announced multiple commercial and R&D milestones. Key developments include an exclusive 10-year white-label license for AgenticPet AI, launch of PetVivo.ai beta, VGP distribution commitment to 7,300 clinics, Health Canada acknowledgement, and progress on biomaterials R&D and clinical pilots.
Management highlighted PetVivo.ai’s demonstrated 50%–90% reduction in veterinary customer acquisition cost, 80%–90% gross margins on the SaaS offering, and near-term commercial expansion into Canada and Europe.
PetVivo (OTCQX: PETV) retracted and replaced its Feb 9, 2026 press release and set a fiscal third quarter 2026 conference call for Tuesday, February 17, 2026 at 5:00 p.m. ET. Results for the quarter ended December 31, 2025 will be released in a prior press release before the call.
Management will present and take questions. Dial-in, conference ID, passcode, and a live webcast with replay are provided; replay will also be posted in the Investors section at petvivo.com/investors.
PetVivo (OTCQX: PETV) will host its Fiscal Third Quarter 2026 conference call on Monday, February 16, 2026 at 5:00 p.m. ET to discuss results for the quarter ended December 31, 2025. A press release with financial results will be issued prior to the call.
Dial-in, conference ID, passcode, and a live webcast with replay will be available; replay also posted in the Investors section at petvivo.com/investors.
PetVivo Holdings (OTCQX: PETV) announced that Health Canada has formally acknowledged Spryng with OsteoCushion Technology as a veterinary medical device for use in Canada. This regulatory acknowledgement is presented as a milestone in the company’s global commercialization strategy. The company said Spryng is a veterinarian-administered intra-articular injectable to support joint health and manage lameness in companion animals and equine athletes. Commercial availability in Canada is not immediate; PetVivo cited distribution setup, Canadian-specific packaging and labeling, and other operational requirements and currently anticipates potential availability in Q2 2026. Spryng is already commercially available in the United States and via select international distributors.